Evidence map›Paper›PMID 32995778›Full record

ArticlebioRxiv : the preprint server for biology2020

Neutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia Virions.

Yue Zheng, Erin T Larragoite, Juan Lama, Isabel Cisneros, Julio C Delgado, Patricia Slev, Jenna Rychert, Emily A Innis, Elizabeth S C P Williams, Mayte Coiras and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 12 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Yue ZhengDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT.
Erin T LarragoiteDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT.
Juan LamaRetroVirox, Inc., San Diego, CA.
Isabel CisnerosRetroVirox, Inc., San Diego, CA.
Julio C DelgadoDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT.
Patricia SlevDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT.
Jenna RychertAssociated Regional and University Pathologists (ARUP) Laboratories, Salt Lake City, UT.
Emily A InnisDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT.
Elizabeth S C P WilliamsDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT.
Mayte CoirasAIDS Immunopathology Unit, National Center of Microbiology (CNM), Instituto de Salud Carlos III, Madrid, Spain.
Matthew T RondinaDepartment of Human Genetics, University of Utah School of Medicine, Salt Lake City, UT.
Adam M SpivakDepartment of Medicine, University of Utah School of Medicine, Salt Lake City, UT.
Vicente PlanellesDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, UT.
University of Utah · USRetroVirox (United States) · USInstituto de Salud Carlos III · ESUniversity Pathologists · US

Funding

Training Program in Microbial PathogenesisT32AI055434 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI MULVEY, MATTHEW A, PLANELLES, VICENTE · 2004 to 2025
$6.0M
Tyrosine Kinase inhibition: The New Front in HIV Cure EffortsR01AI143567 · NIAID · UNIVERSITY OF UTAH · PI COIRAS, MAYTE, PLANELLES, VICENTE · 2019 to 2023
$2.3M
NIAID NIH HHS R01 AI143567NIAID NIH HHS T32 AI055434
6 · The paper itself

Abstract

Antibody neutralization is an important prognostic factor in many viral diseases. To easily and rapidly measure titers of neutralizing antibodies in serum or plasma, we developed pseudovirion particles composed of the spike glycoprotein of SARS-CoV-2 incorporated onto murine leukemia virus capsids and a modified minimal MLV genome encoding firefly luciferase. These pseudovirions provide a practical means of assessing immune responses under laboratory conditions consistent with biocontainment level 2.

Identifiers

PMID32995778
PMCPMC7523104
OpenAlexW3042972491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.